Hypofractionated whole-breast irradiation (HF-WBI) following breast-conserving surgery has produced excellent outcomes, but utilization remains limited. We evaluated the impact of a clinical pathway on adoption of HF-WBI in a large integrated radiation oncology network.
Malolan S. Rajagopalan, MD, John C. Flickinger, MD, Sushil Beriwal, MD, Dwight E. Heron, MD, FACRO, FACR; University of Pittsburgh Cancer Institute
Purpose: Hypofractionated whole-breast irradiation (HF-WBI) following breast-conserving surgery has produced excellent outcomes, but utilization remains limited. We evaluated the impact of a clinical pathway on adoption of HF-WBI in a large integrated radiation oncology network.
Methods: We identified patients aged ≥ 70 years treated for breast cancer or ductal carcinoma in situ (DCIS). Excluded patients were those treated with palliative intent; accelerated partial breast radiation following mastectomy; or with axillary, supraclavicular, or internal mammary fields HF-WBI was defined as ≤ 20 fractions with a dose/fraction ≥ 2.5 Gy. Multivariate analysis identified variables associated with increased HF-WBI utilization.
Results: We identified 2,426 patients meeting the inclusion criteria. HF-WBI utilization increased from 6.5% before pathway modification to 33.8% afterwards (P < .001). For academic physicians, the odds of utilizing HF-WBI increased 4.1 times following publication of the seminal HF-WBI trial and an additional 3.2 times following pathway modification (P < .001 and P = .001, respectively). For community physicians, the odds of HF-WBI did not change following publication but increased 20 times following pathway modification (P < .001). The increased adoption of HF-WBI saves $377,000 annually in our network and $51 million annually if extrapolated nationally.
Conclusions: We found that our implementation of clinical pathways dramatically increased adoption of HF-WBI for breast cancer in a large integrated cancer network. We found no significant change in utilization of HF-WBI among community physicians following publication of a seminal trial for HF-WBI until after clinical pathway implementation, which led to a 20-fold increase. Clinical pathways can be highly effective in changing practice patterns, disseminating evidence, and realizing health care savings.
Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.